// App-Quantinova.ai

: Shall we really say goodbye to first rank symptoms?

Researchers

Presenter

  • A. Heinz

Principal Investigators

  • M. Voss

  • S.M. Lawrie

  • A. Mishara

  • M. Bauer

  • J. Gallinat

  • G. Juckel

  • U. Lang

  • M. Rapp

  • P. Falkai

  • W. Strik

  • J. Krystal

  • A. Abi-Dargham

  • S. Galderisi

Medical Centers

  • University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland

  • Department of Clinical Psychology, Chicago School of Professional Psychology, Los Angeles, USA

  • Social and Preventive Medicine, University of Potsdam, Potsdam, Germany

  • Department of Psychiatry, University of Naples SUN, Naples, Italy

  • Department of Psychiatry and Psychotherapy, Ludwig-Maximilians University, Munich, Germany

  • Division of Psychiatry, University of Edinburgh, Kennedy Tower, Royal Edinburgh Hospital, EdinburghEH10 5HF, UK

  • University Hospital Carl Gustav Carus, Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany

  • Department of Psychiatry and Psychotherapy, Charité University Medicine, Saint-Hedwig Hospital, Humboldt University, Berlin, Germany

  • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA

  • Department of Pathology, Columbia University, New York, NY

  • Department of Psychiatry, Psychotherapy, and Psychosomatic Medicine, Ruhr-University, Bochum, Germany

  • Psychiatric University Clinics (UPK), Basel, Switzerland

  • University Clinic Hamburg-Eppendorf, Clinic and Policlinic for Psychiatry and Psychotherapy, Hamburg, Germany

Locations

  • United States

  • Switzerland

  • Italy

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Schizophrenia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A